Use of Imaging for Preclinical Evaluation

Wang, Zheng J.; Chang, T. Arthur; Slauter, Richard

doi:10.1016/b978-0-12-387815-1.00032-0

Cited by 2 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared to PET, the molecular sensitivity of SPECT is significantly lower. However, considering that the costs are lower, the half-life of the radionuclides used is longer and it uses dual-labelled compounds, this technique is widely applied in clinical practice and preclinical research [85].…”

Section: Neuroimaging Techniquesmentioning

confidence: 99%

Contrast Agents Delivery: An Up-to-Date Review of Nanodiagnostics in Neuroimaging

et al. 2019

View full text Add to dashboard Cite

Neuroimaging is a highly important field of neuroscience, with direct implications for the early diagnosis and progression monitoring of brain-associated diseases. Neuroimaging techniques are categorized into structural, functional and molecular neuroimaging, each possessing advantages and disadvantages in terms of resolution, invasiveness, toxicity of contrast agents and costs. Nanotechnology-based approaches for neuroimaging mostly involve the development of nanocarriers for incorporating contrast agents or the use of nanomaterials as imaging agents. Inorganic and organic nanoparticles, liposomes, micelles, nanobodies and quantum dots are some of the most studied candidates for the delivery of contrast agents for neuroimaging. This paper focuses on describing the conventional modalities used for imaging and the applications of nanotechnology for developing novel strategies for neuroimaging. The aim is to highlight the roles of nanocarriers for enhancing and/or overcome the limitations associated with the most commonly utilized neuroimaging modalities. For future directions, several techniques that could benefit from the increased contrast induced by using imaging probes are presented.

show abstract

Section: Neuroimaging Techniquesmentioning

confidence: 99%

Contrast Agents Delivery: An Up-to-Date Review of Nanodiagnostics in Neuroimaging

et al. 2019

View full text Add to dashboard Cite

show abstract

“…During the last few decades, different non-invasive imaging techniques have been developed for monitoring tumor growth in preclinical and clinical settings. Imaging strategies, including computerized tomography (CT), positron emission tomography (PET), and magnetic resonance (MRI), allow for the detection and measurement of cellular and molecular processes in live animals [3,4,6]. Radionuclide imaging has advantages, such as good sensitivity, but is often costly.…”

Section: Introductionmentioning

confidence: 99%

Near-Infrared Fluorescence Imaging in Preclinical Models of Glioblastoma

Llaguno-Munive,

Villalba-Abascal,

Avilés-Salas

et al. 2023

J. Imaging

View full text Add to dashboard Cite

Cancer is a public health problem requiring ongoing research to improve current treatments and discover novel therapies. More accurate imaging would facilitate such research. Near-infrared fluorescence has been developed as a non-invasive imaging technique capable of visualizing and measuring biological processes at the molecular level in living subjects. In this work, we evaluate the tumor activity in two preclinical glioblastoma models by using fluorochrome (IRDye 800CW) coupled to different molecules: tripeptide Arg-Gly-Asp (RGD), 2-amino-2-deoxy-D-glucose (2-DG), and polyethylene glycol (PEG). These molecules interact with pathological conditions of tumors, including their overexpression of αvβ3 integrins (RGD), elevated glucose uptake (2-DG), and enhanced permeability and retention effect (PEG). IRDye 800CW RGD gave the best in vivo fluorescence signal from the tumor area, which contrasted well with the low fluorescence intensity of healthy tissue. In the ex vivo imaging (dissected tumor), the accumulation of IRDye 800CW RGD could be appreciated at the tumor site. Glioblastoma tumors were presently detected with specificity and sensitivity by utilizing IRDye 800CW RGD, a near-infrared fluorophore combined with a marker of αvβ3 integrin expression. Further research is needed on its capacity to monitor tumor growth in glioblastoma after chemotherapy.

show abstract

Use of Imaging for Preclinical Evaluation

Cited by 2 publications

References 27 publications

Contrast Agents Delivery: An Up-to-Date Review of Nanodiagnostics in Neuroimaging

Contrast Agents Delivery: An Up-to-Date Review of Nanodiagnostics in Neuroimaging

Near-Infrared Fluorescence Imaging in Preclinical Models of Glioblastoma

Contact Info

Product

Resources

About